Filing Flows › Health Care › Caris Life Sciences (CAI)
Caris Life Sciences (CAI) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Caris Life Sciences (CAI) Q3 2026 earnings results →
Q3 2026 Revenue up 27% year over year to $275M · 6¢ of every $1 of revenue kept as net profit · operating margin 7.0%
Caris Life Sciences made $275M in Q3 2026 (+27% Y/Y): Molecular Profiling Services $263M, Pharma Research and Development Services $12.7M. Operating margin 7.0%, net earnings $15.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $275.4M in Q3 2026, up 27% year over year and up 4% from the previous quarter. Molecular Profiling Services was the largest line at 95% of revenue. Molecular Profiling Services added $55.1M year over year (up 27%), 94% of the total change.
Operating profit was $19.3M, a 7.0% margin (down 8.0 points year over year). Operating profit fell $13.3M even though revenue rose $58.5M versus Q3 2025, so costs grew faster than sales. Total costs grew 39% against revenue growth of 27%. The fastest-growing cost line was Research & development (+56%). Net earnings were $15.2M, down 37% year over year. The effective tax rate was 9.6%.
Operating cash flow was −$22.2M. Non-cash charges added back $6.6M of depreciation and amortization and $18.5M of share-based compensation. Working capital and other items used $62.6M. Capital expenditures of $17.5M exceeded it, leaving free cash flow of −$39.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $275M | +27% | 7.0% | $15.2M | −$22.2M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $264M | +45% | 10.2% | −$637K | $28.5M |
| Q1 2026 | 10-Q | May 8, 2026 | $216M | +79% | 2.4% | −$510K | $32.9M |
| Q4 2025 | 10-K | Mar 3, 2026 | $293M | +125% | 30.2% | $82.0M | $44.8M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $217M | +113% | 15.1% | $24.3M | $62.4M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $181M | +81% | -9.9% | −$71.8M | $7.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- Medicare & Medicaid — 39% of its revenue · Stated in 10-K (sentence) · source
Buys from
About Caris Life Sciences
We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. We founded Caris in 2008 with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients.
In its own words, from its 10-K, filed Mar 3, 2026.
Caris Life Sciences against its Services-Medical Laboratories peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +27% against the peers' median +15%. Operating margin: 7.0% against the peers' median 7.0%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CAI Caris Life Sciences | Q3 2026 | $275M | +27% | 7.0% |
| LH Labcorp Holdings | Q3 2026 | $3.8B | +7% | 10.6% |
| DGX Quest Diagnostics | Q3 2026 | $3.1B | +10% | 15.5% |
| NTRA Natera | Q3 2026 | $794M | +34% | -8.6% |
| FTRE Fortrea Holdings | Q3 2026 | $692M | -1% | 2.2% |
| RDNT RadNet | Q2 2026 | $623M | +25% | 6.3% |
| GH Guardant Health | Q3 2026 | $361M | +36% | -36.8% |
| LMRI Lumexa Imaging Holdings | Q2 2026 | $264M | +5% | 8.7% |
| VCYT Veracyte | Q3 2026 | $152M | +15% | 10.9% |
Source: Caris Life Sciences 10-Q on SEC EDGAR · CIK 2019410 · Services-Medical Laboratories
Guidance and outlook
13F: who owns CAI and who is buying
More on CAI
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results
- Caris Life Sciences guidance history: guided vs reported
- Caris Life Sciences operating margin by quarter
- Caris Life Sciences net income by quarter
- Caris Life Sciences free cash flow by quarter
- Caris Life Sciences R&D spending by quarter
- Caris Life Sciences capital expenditures by quarter
- Caris Life Sciences Molecular Profiling Services revenue by quarter
- Caris Life Sciences Pharma Research and Development Services revenue by quarter